Latest news
Archive
- April 2024
- March 2024
- January 2024
- December 2023
- November 2023
- August 2023
- July 2023
- June 2023
- May 2023
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- April 2021
- November 2020
- October 2020
- September 2020
- July 2020
- May 2020
- December 2019
- March 2019
- February 2019
- January 2019
- December 2018
- September 2018
- July 2018
- October 2016
- May 2016
- February 2015
Advancing Equitable COVID-19 Vaccination in Humanitarian Crisis
The World Health Organization (WHO), taking the lead in responding to this pressing issue, selected hera to conduct a study on the complexities of COVID-19 vaccine deployment and administration in humanitarian settings, with a specific focus on populations of concern (PoC). The study was initiated in March 2022 and concluded in March 2023, and encompassed case studies in multiple countries deeply affected by humanitarian crises: Cox's Bazar (Bangladesh), Colombia, the Democratic Republic of the Congo (DRC), Iraq, South Sudan, and Syria.
Fact sheet on the Maternal Health of Women and Girls of African Descent in the Americas
This fact sheet was developed by the United Nations Population Fund (UNFPA) with the support of a hera team that included Adria Armbrister, Marianne Eelens, and Alejandra Martinez.
Gender, HIV and Youth Mainstreaming Strategy of the Seed Knowledge Initiative (SKI)
SKI is comprised of 16 partner organisations in Malawi, Zambia, Zimbabwe and South Africa with the aim of improving farmer-led seed knowledge systems and helping smallholder farmers to become more seed, food and nutritionally secure.
Final evaluation of the project Consolidating Cardiovascular Services at the national cardiac centre in Mongolia
hera partner Michèle Kosremelli Asmar is part of the PROMAN consortium implementing the Third-Party Monitoring of the Lebanon Health Programme for Syrian Refugees and Vulnerable Lebanese Population funded by the European Union through the MADAD fund.
Mozambique - MTR cooperation Flanders Mozambique - Flanders BuZa
hera's MTR evaluated implementation progress, identified challenges, and provided recommendations for improvement. The findings helped shape the subsequent CSP phase, emphasizing innovation and addressing key healthcare issues.
External Evaluation of the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP) 2013-2017
hera was selected to conduct the fourth external evaluation of the HRP covering the period from January 2013 to December 2017.
Bridging the Gap in Health Care Services in DRC with the ASSR Programme
Operating in four provinces of DRC – Nord Ubangi, Kasai, Kasai Central, and Maniema – the ASSR programme targets an estimated population of 9 million. The anticipated maximum value of the ASSR programme over its 18-month duration is £35 million.
Universal Health Coverage for Sexual and Reproductive Health in the Asia-Pacific Region
The study of universal health coverage for sexual and reproductive health in the Asia-Pacific Region was undertaken by hera under contract by the United Nations Population Fund Asia and Pacific Regional Office.
Technical support to the 3MDG Fund multi-donor program from 2012 to 2016
From 2012 to 2016, hera provided technical support to the 3MDG Fund multi-donor program in Myanmar, delivering insights through a detailed cost-effectiveness analysis of two key components of the 3MDG program.
Assessing the Impact: BMGF & DFID's Reproductive Health Programmes in Low- and Middle-Income Countries
In an effort to promote reproductive health and accessibility to quality-assured reproductive health commodities in low- and middle-income countries, the Bill & Melinda Gates Foundation (BMGF) and the Department for International Development (DFID), now known as the Foreign, Commonwealth & Development Office (FCDO), rolled out two independent, yet complementary, programmes geared towards ensuring hormonal contraceptives become more readily available, of high quality and affordable.